MedTrace Logo

Aberrant Expression of CD56 in Patients With Hematologic Malignancies.

NCT04546945 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 38

Last updated 2026-03-18

No results posted yet for this study

Summary

CD56(cluster of differentiation 56) was found to be ectopically expressed in multiple myeloma . A met analysis indicated that CD56 over expression may be an adverse prognostic factor in AML. To the best of our knowledge, no available data the expression pattern of CD56 in other Hematologic malignancies. This work is designed to evaluate the expression pattern of CD56 in hematologic malignancies.

Conditions

Interventions

DIAGNOSTIC_TEST

CD56

detection of CD56 by flow cytometry

Sponsors & Collaborators

  • Asmaa Hassan mohamed Abdel Mawjoud

    lead OTHER

Principal Investigators

  • Maged S Mahmoud, prof · Assiut University

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2027-03-20
Primary Completion
2027-06-30
Completion
2027-12-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04546945 on ClinicalTrials.gov